Browse medicines, page 8 of 37

Use listed on the medicine record

And pediatric patients ages 3 years and older for the reversal of soft-tissue anesthesia, i

Use listed on the medicine record

The treatment of adult patients

Use listed on the medicine record

Moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

Use listed on the medicine record

Postoperative pain

Use listed on the medicine record

Pretreatment against the lethal effects of soman nerve agent poisoning

Use listed on the medicine record

Coronavirus disease 2019

Use listed on the medicine record

Serum phosphorus

Use listed on the medicine record

Pulmonary arterial hypertension

Use listed on the medicine record

Insomnia characterized by difficulties with sleep onset and/or sleep maintenance

Use listed on the medicine record

Testosterone replacement therapy

Use listed on the medicine record

The signs and symptoms of idiopathic Parkinson's disease

Use listed on the medicine record

Moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers

Use listed on the medicine record

Vigabatrin tablets are indicated for the treatment of: Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; Vigabatrin tablets are not indicated as a first line agent ( 1.1 ) Infantile Spasms - monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss ( 1.2 ) 1.1 Refractory Complex Partial Seizures (CPS) Vigabatrin tablets are indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with…

Use listed on the medicine record

Previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation

Use listed on the medicine record

none

Use listed on the medicine record

Regulating immunity

Use listed on the medicine record

Hypertension, to lower blood pressure

Use listed on the medicine record

Wakefulness

Use listed on the medicine record

HIV-1 infection

Use listed on the medicine record

Auranofin Capsules (auranofin) is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. Auranofin Capsules should be added to a comprehensive baseline program, including non-drug therapies. Unlike anti-inflammatory drugs, Auranofin Capsules does not produce an immediate response.

Use listed on the medicine record

Moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis fac

Use listed on the medicine record

Hypertension, to lower blood pressure

Use listed on the medicine record

Dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism

Use listed on the medicine record

Regul Oil Cleansing Cream indications

Use listed on the medicine record

The following infections caused by susceptible Gram-negative microorganisms

Use listed on the medicine record

Relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease

Use listed on the medicine record

The treatment of adult patients

Use listed on the medicine record

Treatment of patients with advanced prostate cancer

Use listed on the medicine record

Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies ( 14 )]

Use listed on the medicine record

Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Use listed on the medicine record

VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Use listed on the medicine record

The treatment of patients

Use listed on the medicine record

The short-term treatment

Use listed on the medicine record

Step1: After using the basic lotion Step2: Apply appropriate amount to the palm, smear on the whole face, neck and other easily exposed parts Step3: Apply evenly and gently so that it absorbs into a film

Use listed on the medicine record

①Take out a bottle of essence from the box ②Unscrew the top cap and squeeze the essence intothe palm of your hand ③Apply evenly on the face and neck,gently massage until fully moisturized

Use listed on the medicine record

The topical treatment of atopic dermatitis

Use listed on the medicine record

Locally confined Stage B 2 -C and Stage D 2 metastatic carcinoma of the prostate

Use listed on the medicine record

Hypertension

Use listed on the medicine record

Thrombocytopenia

Use listed on the medicine record

Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density li

Use listed on the medicine record

Severe hypoglycemia

Use listed on the medicine record

Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma

Use listed on the medicine record

VASCEPA ® (icosapent ethyl) is indicated: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

Use listed on the medicine record

Endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative

Use listed on the medicine record

• helps prevent sunburn • if used as directed with other sun protection measures (see Directions). Decreases the risk of skin cancer and early skin aging caused by the sun.

Use listed on the medicine record

Tear off the patch,Stick it 5 to 8 centimeters belowthe base of your palm, Place the product on the back of your neck

Use listed on the medicine record

Insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies ( 14

Use listed on the medicine record

Advanced breast

Use listed on the medicine record

Low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol

Use listed on the medicine record

Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.

Use listed on the medicine record

Pulmonary arterial hypertension

Use listed on the medicine record

The following therapeutic uses

Use listed on the medicine record

Depo-subQ provera 104 is indicated in females of reproductive age for: • Prevention of pregnancy and • Management of endometriosis-associated pain. Depo-subQ provera 104 is a progestin that is indicated in females of reproductive age for: • Prevention of pregnancy. ( 1 ) • Management of endometriosis-associated pain. ( 1 ) Limitations of Use : Use of depo-subQ provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate.

Use listed on the medicine record

Management of mild to moderate pain

Use listed on the medicine record

Moderate to severe dementia of the Alzheimer's type